Skip to main content
NCBI home page
Sarcoma logoLink to Sarcoma
. 2000 Mar;4(1-2):31–35. doi: 10.1155/S1357714X00000062

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

Ole S Nielsen 1,✉, Per Dombernowsky 2, Henning Mouridsen 3, Søren Daugaard 4, Martine Van Glabbeke 5, Anne Kirkpatrick 5, Jaap Verweij 6
PMCID: PMC2408358  PMID: 18521432

Abstract

Purpose. Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have suggested activity of other analogues. In two studies the EORTC STBSG tested whether epirubicin (epi) is an alternative to standard dose dox in the treatment of chemonaive patients with advanced soft tissue sarcoma. The present report gives the final results of these studies.

Patients/Methods. In the first study 210 patients were randomized to receive either dox or epi both at a dose of 75 mg/m2 given as bolus injection at 3-week intervals. In the second study 334 patients were randomized to dox 75 mg/m2, epi 150 mg/m2 or epi 50 mg/m2 days 1–3, all given as bolus injection at 3-week intervals.

Results. In the first study no differences in median survival and duration of response were found. Of 167 evaluable patients the response rate was slightly in favour of dox (23% vs 18%) but at the expense of more toxicity.These data could suggest that increasing the epi dose may lead to a greater antineoplastic effect with acceptable toxicity. In the second study 15% of 314 evaluable patients had an objective tumour response. There were no differences between the three groups with regard to response rate, progression-free and overall survival, but both dose schedules of epi were more myelotoxic than dox.

Conclusion. Regardless of schedule and dose, epi is not superior to dox in the treatment of patients with advanced soft tissue sarcomas. In addition, the results illustrate that the data from small studies of single institutions should always be confirmed by large multi-institutional studies before being taken for granted.

Full Text

The Full Text of this article is available as a PDF (102.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackledge G., van Oosterom A., Mouridsen H., Steward W. P., Buesa J., Thomas D., Sylvester R., Rouesse J. Doxorubicin in relapsed soft tissue sarcoma: justification of phase II evaluation of new drugs in this disease. An EORTC Soft Tissue and Bone Sarcoma Group Study. Eur J Cancer. 1990 Feb;26(2):139–141. doi: 10.1016/0277-5379(90)90296-6. [DOI] [PubMed] [Google Scholar]
  2. Borden E. C., Amato D. A., Rosenbaum C., Enterline H. T., Shiraki M. J., Creech R. H., Lerner H. J., Carbone P. P. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987 Jun;5(6):840–850. doi: 10.1200/JCO.1987.5.6.840. [DOI] [PubMed] [Google Scholar]
  3. Bramwell V. H., Mouridsen H. T., Mulder J. H., Somers R., Van Oosterom A. T., Santoro A., Thomas D., Sylvester R., Markham D. Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. Eur J Cancer Clin Oncol. 1983 Aug;19(8):1097–1104. doi: 10.1016/0277-5379(83)90034-2. [DOI] [PubMed] [Google Scholar]
  4. Bull F. E., Von Hoff D. D., Balcerzak S. P., Stephens R. L., Panettiere F. J. Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study. Cancer Treat Rep. 1985 Feb;69(2):231–233. [PubMed] [Google Scholar]
  5. Garcia A. A., Kempf R. A., Rogers M., Muggia F. M. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. Ann Oncol. 1998 Oct;9(10):1131–1133. doi: 10.1023/a:1008439013169. [DOI] [PubMed] [Google Scholar]
  6. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984 Nov;2(11):1281–1288. doi: 10.1200/JCO.1984.2.11.1281. [DOI] [PubMed] [Google Scholar]
  7. Jelić S., Vuletić L., Milanović N., Tomasević Z., Kovcin V. High-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Tumori. 1990 Oct 31;76(5):467–471. doi: 10.1177/030089169007600510. [DOI] [PubMed] [Google Scholar]
  8. Launchbury A. P., Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993 Jul;19(3):197–228. doi: 10.1016/0305-7372(93)90036-q. [DOI] [PubMed] [Google Scholar]
  9. Mouridsen H. T., Bastholt L., Somers R., Santoro A., Bramwell V., Mulder J. H., van Oosterom A. T., Buesa J., Pinedo H. M., Thomas D. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol. 1987 Oct;23(10):1477–1483. doi: 10.1016/0277-5379(87)90089-7. [DOI] [PubMed] [Google Scholar]
  10. Nielsen O. S., Dombernowsky P., Mouridsen H., Crowther D., Verweij J., Buesa J., Steward W., Daugaard S., van Glabbeke M., Kirkpatrick A. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. Br J Cancer. 1998 Dec;78(12):1634–1639. doi: 10.1038/bjc.1998.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. O'Bryan R. M., Luce J. K., Talley R. W., Gottlieb J. A., Baker L. H., Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer. 1973 Jul;32(1):1–8. doi: 10.1002/1097-0142(197307)32:1<1::aid-cncr2820320101>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  12. Palumbo R., Neumaier C., Cosso M., Bertero G., Raffo P., Spadini N., Valente S., Villani G., Pastorino M., Toma S. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer. 1999 Jan;35(1):66–72. doi: 10.1016/s0959-8049(98)00293-7. [DOI] [PubMed] [Google Scholar]
  13. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Plosker G. L., Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993 May;45(5):788–856. doi: 10.2165/00003495-199345050-00011. [DOI] [PubMed] [Google Scholar]
  15. Reichardt P., Tilgner J., Hohenberger P., Dörken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998 Apr;16(4):1438–1443. doi: 10.1200/JCO.1998.16.4.1438. [DOI] [PubMed] [Google Scholar]
  16. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537–1545. doi: 10.1200/JCO.1995.13.7.1537. [DOI] [PubMed] [Google Scholar]
  17. Suit H. Regaud Lecture, Granada 1994. Tumors of the connective and supporting tissues. Radiother Oncol. 1995 Feb;34(2):93–104. doi: 10.1016/0167-8140(95)01512-f. [DOI] [PubMed] [Google Scholar]
  18. Verweij J., Mouridsen H. T., Nielssen O. S., Woll P. J., Somers R., van Oosterom A. T., Van Glabbeke M., Tursz T. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol. 1995 Oct;20(3):193–201. doi: 10.1016/1040-8428(94)00146-K. [DOI] [PubMed] [Google Scholar]
  19. Wexler L. H. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin Oncol. 1998 Aug;25(4 Suppl 10):86–92. [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES